Clareo Health | Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Inoperable estrogen receptor positive and HER2 negative breast cancer.
Postmenopausal status.
Tumor tissue (archived acceptable) available for biomarker studies. For Phase 2 Part 2 - CCND1 amplification and/or loss of p16 as determined by the central laboratory.
Acceptable bone marrow, liver and kidney function.
You may not be if
Prior or concomitant treatment for advanced breast cancer.
Other major cancer in the past 3 years.
Important cardiovascular events in the past 6 months.
